RSS Cellerix

RSS Cellerixhttp://www.cellerix.atela.biz/index.phpGeneral Shareholder Meeting Cellerix, S.A.http://www.cellerix.atela.biz/index.php/Press-Room/Last-News/General-Shareholder-Meeting-Cellerix-S.A Junta General de Accionistas de lasociedad Cellerix, S.A. a celebrarse en el domicilio social el día 3 de mayo de2011, a las 11:00 horas, TiGenix announces proposed combination with Cellerix and capital increase through a public rights offeringhttp://www.cellerix.atela.biz/index.php/Press-Room/Last-News/TiGenix-announces-proposed-combination-with-Cellerix-and-capital-increase-through-a-public-rights-offering Combination will create the European cell therapy leader with two marketed products and a promising pipeline CELLERIX DISCLOSES RESULTS OF PHASE IIa CLINICAL TRIAL OF Cx601 PRODUCThttp://www.cellerix.atela.biz/index.php/Press-Room/Last-News/CELLERIX-DISCLOSES-RESULTS-OF-PHASE-IIa-CLINICAL-TRIAL-OF-Cx601-PRODUCT Results and outcome of the study demonstrate very good safety and efficacy profiles Cellerix appoints José Luis Bravo VP Global Medical and Regulatoryhttp://www.cellerix.atela.biz/index.php/Press-Room/Last-News/Cellerix-appoints-Jose-Luis-Bravo-VP-Global-Medical-and-RegulatoryCellerix raises €27 million in a first closing http://www.cellerix.atela.biz/index.php/Press-Room/Last-News/Cellerix-raises-27-million-in-a-first-closing YSIOS, LSP and VENTECH led this financing round together with Genetrix and also joined by new investors Gamida Cell and Cellerix Partner on Feasibility Studyhttp://www.cellerix.atela.biz/index.php/Press-Room/Last-News/Gamida-Cell-and-Cellerix-Partner-on-Feasibility-Study Pre-clinical study will test new method of improving clinical efficacy of expanded populations of adult stem cells obtained from adipose tissue Cellerix, European Excellence Award http://www.cellerix.atela.biz/index.php/Press-Room/Last-News/Cellerix-European-Excellence-AwardHospital Universitario La Paz, 3 de julio 2009 – Esperanza Aguirre presenta en rueda de prensa los resultados de Cx401 (Ontaril®) del fase II así como del inicio del ensayo FATT2http://www.cellerix.atela.biz/index.php/Press-Room/Last-News/Hospital-Universitario-La-Paz-3-de-julio-2009-Esperanza-Aguirre-presenta-en-rueda-de-prensa-los-resultados-de-Cx401-Ontaril-R-del-fase-II-asi-como-del-inicio-del-ensayo-FATT2El Global - Cellerix receives the National Rhttp://www.cellerix.atela.biz/index.php/Press-Room/Last-News/El-Global-Cellerix-receives-the-National-R-D-I-award-in-the-8th-Fundamed-Awards-Ceremony Cellerix was recognized for its contribution to cell therapy and investigation in Spain Cinco Días - Cell Therapy that fulfills its promisehttp://www.cellerix.atela.biz/index.php/Press-Room/Last-News/Cinco-Dias-Cell-Therapy-that-fulfills-its-promise The Spanish biopharmaceutical company Cellerix is developing the first pharmaceutical product based on adipose tissue derived adult stem cells to be approved in Europe El Mundo - Next generation pharmaceuticals found in fathttp://www.cellerix.atela.biz/index.php/Press-Room/Last-News/El-Mundo-Next-generation-pharmaceuticals-found-in-fat Cellerix, a company founded by the current Spanish Minister for Science and Innovation, Cristina Garmendia, hopes to launch a product based on fat derived stem cells in 2011 to help heal anal fistulas Cellerix’s Cx601 designated Orphan Medicinal product by the EMEAhttp://www.cellerix.atela.biz/index.php/content/view/full/346 Third medicine developed by Cellerix that obtains this designation Cellerix starts a multicenter trial for its medicine Cx601http://www.cellerix.atela.biz/index.php/Press-Room/Last-News/Cellerix-starts-a-multicenter-trial-for-its-medicine-Cx601 Cx601 is the allogenic version of Ontaril®, used for treating perianal fistulas Cellerix names board member Eduard E Holdener http://www.cellerix.atela.biz/index.php/Press-Room/Last-News/Cellerix-names-board-member-Eduard-E-HoldenerAlfonso Camba appointed VP Manufacturing Operations of Cellerixhttp://www.cellerix.atela.biz/index.php/Press-Room/Last-News/Alfonso-Camba-appointed-VP-Manufacturing-Operations-of-CellerixOntaril® closer to the markethttp://www.cellerix.atela.biz/index.php/Press-Room/Last-News/Ontaril-R-closer-to-the-market Cellerix ends the recruitment for the first Phase III trial It is sticking to the planned schedule, which is expected to be commercialized by 2011 Joël Jean-Mairet to become Chairman of Cellerixhttp://www.cellerix.atela.biz/index.php/Press-Room/Last-News/Joel-Jean-Mairet-to-become-Chairman-of-Cellerix Eduardo González appointed Director. Cellerix obtains a 10M€ debt facility with ETV Capitalhttp://www.cellerix.atela.biz/index.php/content/view/full/280 The biopharmaceutical company will be able to finalize clinical development of Ontaril®, its treatment for Perianal Fistulas for Crohn and non-Crohn patients. The Lilly Foundation and Cellerix present the book “Cell Therapy”http://www.cellerix.atela.biz/index.php/Press-Room/Last-News/The-Lilly-Foundation-and-Cellerix-present-the-book-Cell-Therapy Cell Therapy is the first book in the world published about a field that is revolutionizing medical practice Cellerix registers the name Ontaril® for its medicine Cx401http://www.cellerix.atela.biz/index.php/Press-Room/Last-News/Cellerix-registers-the-name-Ontaril-R-for-its-medicine-Cx401 Cellerix has registered the name Ontaril® for its medicine Cx401.